more information regarding the EASL presentations.)
-- The lead clinical candidate from the nucleotide prodrug program,
IDX184, is on track for an investigational new drug (IND)
application submission in the first half of 2008. Based on the
preclinical pharmacology and toxicology profile of IDX184
demonstrated to date, the company anticipates that the first-in-
man clinical trial should be initiated in the second half of
-- Idenix also reported positive preclinical data from its HCV
protease inhibitor program, with internally discovered compounds
exhibiting potency in the HCV replicon system and good
pharmacokinetic profiles in several animal species.
"We have made significant progress in the last six months in the discovery and development of our HCV and HIV programs," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "We are very pleased with the initial antiviral activity and safety data generated in the IDX899 clinical development program. Based on the profile of IDX899 exhibited to date, we believe that IDX899 could play an important role in the treatment of patients with HIV."
Sommadossi continued, "Our expertise and focus on antiviral discovery and development enables us to rapidly advance our programs through IND-enabling preclinical studies, proof-of-concept testing and into phase II clinical studies. With a comprehensive HCV discovery program in each of the major classes of direct-acting HCV antivirals, we are uniquely positioned to be one of the first companies to develop our own specifically targeted antiviral therapy for HCV (STAT-C)."
For the first quarter ended March 31, 2008, Idenix reported total
revenues of $2.0 million, compared with total revenues of $24.8 million in
the first quarter of 2007. Th
|SOURCE Idenix Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved